Columbia Asset Management Has $5.74 Million Position in Stryker Co. (NYSE:SYK)

Columbia Asset Management decreased its position in Stryker Co. (NYSE:SYK - Free Report) by 5.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,933 shares of the medical technology company's stock after selling 907 shares during the quarter. Stryker comprises approximately 1.0% of Columbia Asset Management's holdings, making the stock its 25th largest position. Columbia Asset Management's holdings in Stryker were worth $5,737,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of SYK. Vanguard Group Inc. lifted its holdings in Stryker by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock valued at $11,773,213,000 after acquiring an additional 252,188 shares during the last quarter. State Street Corp raised its holdings in shares of Stryker by 2.2% in the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company's stock worth $5,279,788,000 after purchasing an additional 316,404 shares in the last quarter. Geode Capital Management LLC lifted its stake in Stryker by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock valued at $2,539,033,000 after purchasing an additional 168,436 shares during the last quarter. Norges Bank acquired a new position in Stryker in the fourth quarter worth approximately $1,710,744,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Stryker by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,985,045 shares of the medical technology company's stock worth $714,715,000 after acquiring an additional 48,819 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Remove Ads

Stryker Stock Down 2.5 %

NYSE SYK traded down $9.34 during trading on Thursday, hitting $368.12. 3,306,021 shares of the company traded hands, compared to its average volume of 1,306,429. The company has a market capitalization of $140.51 billion, a P/E ratio of 47.44, a PEG ratio of 2.93 and a beta of 0.95. The business has a fifty day simple moving average of $382.64 and a 200 day simple moving average of $374.41. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company posted $3.46 earnings per share. As a group, sell-side analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.91%. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Analyst Ratings Changes

SYK has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price target on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. StockNews.com lowered shares of Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. JPMorgan Chase & Co. raised their price objective on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Canaccord Genuity Group boosted their target price on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Finally, The Goldman Sachs Group set a $422.00 target price on Stryker in a research report on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $421.90.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.50% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.